Anisa Dias Nur'AIni
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Anisa Dias Nur'AIni has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Andang Nurhuda
Department of Chemistry Education, Faculty of Mathematics and Natural Sciences, Universitas Negeri Surabaya, Surabaya 60231, Indonesia
2 shared publications - Andika Julyanto Syachputra
Department of Tropical Biology, Faculty of Biology, Universitas Gadjah Mada, Yogyakarta
2 shared publications - Fiki Muhammad Ridho
Faculty of Dental Medicine, Universitas Airlangga, Surabaya, Indonesia, Indonesia
2 shared publications - Hamnah Al Atsariyah
Department of Pharmacy, Faculty of Pharmacy, Universitas Ahmad Dahlan, Yogyakarta 55164, Indonesia
1 shared publication - Kamailiya Ulfah
Veterinarian Profession Program, Faculty of Veterinary Medicine, Universitas Airlangga. Surabaya, Indonesia
1 shared publication - Muhamad Faqih
Department of Bioprocess and Polymer Engineering, Faculty of Chemical and Energy Engineering, Universiti Teknologi Malaysia, 81310 Skudai, Johor, Malaysia
1 shared publication
Latest Publications
- Open Access
- 19 March 2025
- Published by Editorial de la Universidad de Granada in Ars Pharmaceutica (Internet)
- Vol. 66 (2) , 225-232
La curcumina y sus derivados como posibles candidatos antivirales contra la viruela del mono (mpox): una revisión de estudios computacionales
Introduction: Monkeypox (mpox) is an infectious disease caused by the mpox virus that is of global health concern because the outbreak, as of May 2023, has affected more than 80,000 people in hundreds of countries. Currently, there is no specific treatment, including antivirals, for mpox patients. Exploration of active compounds for mpox continues, one of which is curcumin and its derivatives. Curcumin is a polyphenol compound predominantly found in turmeric which has been documented to have antiviral effects. Therefore, this study aims to explore studies investigating the potential of curcumin and its derivatives as antiviral candidates in targeting mpox. Method: Literature published from inception to 2024 in ScienceDirect, PubMed, Scopus, and Google Scholar was searched. Keywords used in this search included curcuma, curcumin, tetrahydrocurcumin, demethoxycurcumin, bisdemethoxycurcumin, turmeric, monkeypox, and mpox. Results: The literature search results found five computational studies involving the compound curcumin and its derivatives, including tetrahydroxycurcumin and demethoxycurcumin. All studies showed that curcumin and its derivatives have better binding affinity with mpox proteins compared to control of several antivirals. Curcumin and its derivatives have strong potential in inhibiting mpox virus replication and modulating the immune system. Conclusions: This review concludes that curcumin and its derivatives have potential as antiviral candidates for mpox. However, related studies remain limited and confined to computational studies. Further preclinical experimental and clinical studies are needed to confirm their effectiveness and mechanisms of action.
- 19 March 2025
- Published by Editorial de la Universidad de Granada in Ars Pharmaceutica (Internet)
- Vol. 66 (2) , 225-232
Open AccessLa curcumina y sus derivados como posibles candidatos antivirales contra la viruela del mono (mpox): una revisión de estudios computacionales
Introduction: Monkeypox (mpox) is an infectious disease caused by the mpox virus that is of global health concern because the outbreak, as of May 2023, has affected more than 80,000 people in hundreds of countries. Currently, there is no specific treatment, including antivirals, for mpox patients. Exploration of active compounds for mpox continues, one of which is curcumin and its derivatives. Curcumin is a polyphenol compound predominantly found in turmeric which has been documented to have antiviral effects. Therefore, this study aims to explore studies investigating the potential of curcumin and its derivatives as antiviral candidates in targeting mpox. Method: Literature published from inception to 2024 in ScienceDirect, PubMed, Scopus, and Google Scholar was searched. Keywords used in this search included curcuma, curcumin, tetrahydrocurcumin, demethoxycurcumin, bisdemethoxycurcumin, turmeric, monkeypox, and mpox. Results: The literature search results found five computational studies involving the compound curcumin and its derivatives, including tetrahydroxycurcumin and demethoxycurcumin. All studies showed that curcumin and its derivatives have better binding affinity with mpox proteins compared to control of several antivirals. Curcumin and its derivatives have strong potential in inhibiting mpox virus replication and modulating the immune system. Conclusions: This review concludes that curcumin and its derivatives have potential as antiviral candidates for mpox. However, related studies remain limited and confined to computational studies. Further preclinical experimental and clinical studies are needed to confirm their effectiveness and mechanisms of action.
- Open Access
- 23 November 2024
- Published by Universidad Cientifica del Sur in Revista Científica Odontológica
- Vol. 12 (4) , e222
PRE-CLINICAL AND CLINICAL EFFICACY OF CURCUMIN AS AN ANTI-INFLAMMATORY AGENT FOR PERIODONTITIS. A SYSTEMATIC REVIEW
Introduction: There is ongoing exploration into herbal treatments to identify adjunct therapies with minimal side effects. One such treatment involves curcumin from turmeric (Curcuma longa). This study aims to review the efficacy of curcumin as an anti-inflammatory agent for periodontitis along with the mechanisms of action involved. Methods: A systematic review of pre-clinical and clinical studies published on Scopus, PubMed, ScienceDirect, and Google Scholar up to May 2024 was employed following the PRISMA guidelines. Three tools were used for risk of bias assessment, namely the QUIN tool for in vitro studies, the SYRCLE’s RoB for in vivo studies, and the Cochrane RoB 2 for RCTs. Finally, nineteen studies were included for review. Results: This study highlights curcumin’s efficacy in addressing periodontitis through diverse mechanisms. Curcumin demonstrated efficacy in attenuating inflammation within periodontal tissue by inhibiting several pro-inflammatory cytokines and mediators such as interleukin (IL)-1, IL-6, tumor necrosis factor (TNF)-α, matrix metalloproteinases (MMPs), prostaglandin E2 (PGE2), cyclooxygenase (COX)-2, while concurrently increasing IL-4 and IL-10. In addition, several transcription factors such as nuclear factor-kappa B (NF-κB) and signal transducer and activator of transcription 1 (STAT1) were also inhibited by curcumin. Administration of curcumin has additionally been demonstrated to reduce other biomarkers of periodontitis, including C-reactive protein (CRP), alkaline phosphatase (ALP), and procalcitonin (PCT). Conclusion: Curcumin has been shown to be effective as an adjunct therapeutic agent for periodontitis due to its anti-inflammatory effects by reducing the inflammatory response through a diverse range of mechanisms of action.
- 23 November 2024
- Published by Universidad Cientifica del Sur in Revista Científica Odontológica
- Vol. 12 (4) , e222
Open AccessPRE-CLINICAL AND CLINICAL EFFICACY OF CURCUMIN AS AN ANTI-INFLAMMATORY AGENT FOR PERIODONTITIS. A SYSTEMATIC REVIEW
Introduction: There is ongoing exploration into herbal treatments to identify adjunct therapies with minimal side effects. One such treatment involves curcumin from turmeric (Curcuma longa). This study aims to review the efficacy of curcumin as an anti-inflammatory agent for periodontitis along with the mechanisms of action involved. Methods: A systematic review of pre-clinical and clinical studies published on Scopus, PubMed, ScienceDirect, and Google Scholar up to May 2024 was employed following the PRISMA guidelines. Three tools were used for risk of bias assessment, namely the QUIN tool for in vitro studies, the SYRCLE’s RoB for in vivo studies, and the Cochrane RoB 2 for RCTs. Finally, nineteen studies were included for review. Results: This study highlights curcumin’s efficacy in addressing periodontitis through diverse mechanisms. Curcumin demonstrated efficacy in attenuating inflammation within periodontal tissue by inhibiting several pro-inflammatory cytokines and mediators such as interleukin (IL)-1, IL-6, tumor necrosis factor (TNF)-α, matrix metalloproteinases (MMPs), prostaglandin E2 (PGE2), cyclooxygenase (COX)-2, while concurrently increasing IL-4 and IL-10. In addition, several transcription factors such as nuclear factor-kappa B (NF-κB) and signal transducer and activator of transcription 1 (STAT1) were also inhibited by curcumin. Administration of curcumin has additionally been demonstrated to reduce other biomarkers of periodontitis, including C-reactive protein (CRP), alkaline phosphatase (ALP), and procalcitonin (PCT). Conclusion: Curcumin has been shown to be effective as an adjunct therapeutic agent for periodontitis due to its anti-inflammatory effects by reducing the inflammatory response through a diverse range of mechanisms of action.